Can I Take Glycine with MK-677 (Ibutamoren)?

What Is MK-677 (Ibutamoren) and How Does It Work?

MK-677 is a synthetic, orally active ghrelin receptor agonist that stimulates the pituitary to release GH and, downstream, raises insulin-like growth factor-1 (IGF-1). It is not FDA-approved and is sold strictly for research purposes, yet it circulates widely in bodybuilding and longevity communities.

Mechanism at the Ghrelin Receptor

Ghrelin binds the growth hormone secretagogue receptor 1a (GHSR-1a). MK-677 mimics ghrelin at this receptor without requiring injection [1]. A 1998 dose-escalation study published in the Journal of Clinical Endocrinology and Metabolism (N=32) showed that 25 mg daily raised 24-hour mean GH concentration by 97% and IGF-1 by 52% after two weeks of oral dosing [2].

Duration and Pharmacokinetics

MK-677 has a plasma half-life of roughly 24 hours, allowing once-daily dosing [2]. It is not metabolized by cytochrome P450 3A4 (CYP3A4) to any clinically meaningful degree, which matters when evaluating drug interactions. The FDA has not reviewed any pharmacokinetic data for MK-677 in an approved label because no indication has been approved [3].

Known Side Effects Relevant to This Stack

The principal adverse effects documented in human trials are [2]:

• Increased appetite (ghrelin-mediated)
• Transient lower-limb edema
• Fasting hyperglycemia and reduced insulin sensitivity
• Morning lethargy at higher doses (25 mg and above)

Each of those effects interacts, to varying degrees, with glycine's pharmacology.

What Is Glycine and What Does It Do Physiologically?

Glycine is the simplest amino acid. It functions as an inhibitory neurotransmitter in the spinal cord and brainstem, a co-agonist at the NMDA glutamate receptor in the brain, and the rate-limiting precursor for collagen and glutathione biosynthesis [4].

Sleep Architecture Effects

A 2012 randomized crossover trial (N=11) published in Sleep and Biological Rhythms found that 3 g of oral glycine taken 1 hour before bed shortened sleep-onset latency and improved subjective sleep quality compared with placebo [5]. A follow-up study confirmed reduced daytime fatigue after nocturnal glycine supplementation [6].

Glycemic and Insulin Effects

Glycine is an incretin-active amino acid. It stimulates glucagon-like peptide-1 (GLP-1) and glucagon secretion from pancreatic alpha cells [7]. A 2018 randomized trial in Clinical Nutrition (N=42) showed that 5 g of glycine co-ingested with a glucose load reduced the postprandial glucose area under the curve by 12% compared with glucose alone [8]. That glucose-lowering action is directly relevant when stacking with MK-677, which raises fasting glucose.

Collagen and Connective Tissue

Collagen is approximately 33% glycine by amino acid composition. Without sufficient glycine, collagen synthesis is substrate-limited regardless of the downstream IGF-1 signal [9]. Dietary glycine intake from food averages 1.5 to 3 g per day in Western diets, a level that some researchers argue falls short of the 10 to 15 g per day required to saturate collagen synthesis pathways [9].

Is the MK-677 and Glycine Interaction Pharmacokinetic or Pharmacodynamic?

The interaction is pharmacodynamic, not pharmacokinetic. That distinction matters for safety planning.

No Shared Metabolic Enzymes

Glycine is metabolized primarily through the glycine cleavage system (GCS) in liver mitochondria and through conjugation reactions that produce hippurate and bile acid conjugates [4]. MK-677 does not meaningfully induce or inhibit these pathways. MK-677, for its part, is not a known substrate, inducer, or inhibitor of CYP1A2, CYP2D6, or CYP3A4 [2]. No published pharmacokinetic interaction study has identified altered plasma concentrations of either compound when co-administered.

Shared Growth Hormone Pathway

This is the clinically significant overlap. Glycine stimulates GH release through a mechanism separate from the ghrelin receptor. A 1990 study in Acta Endocrinologica (N=19) showed that 6.75 g of oral glycine acutely raised serum GH by roughly 3.5-fold above baseline at 90 minutes post-dose [10]. MK-677 raises GH through GHSR-1a activation. Because the two stimuli act on different upstream pathways converging on the same somatotroph output, co-administration may produce an additive GH pulse rather than a synergistic one. No human study has directly measured the combined GH response, but additive effects are biologically plausible.

Insulin Resistance vs. Glycine's Insulin-Sensitizing Signal

MK-677 at 25 mg daily raised fasting blood glucose from a mean of 94 to 102 mg/dL over 12 months in the MK-677-001 extension trial (N=65) [11]. Glycine's GLP-1-stimulating and direct insulin-sensitizing properties work in the opposite direction [7, 8]. The net glycemic effect of the combination has not been characterized in a controlled trial, but the partial offset is mechanistically coherent and clinically worth tracking.

Does Taking Glycine With MK-677 Improve Sleep Quality?

Both compounds independently support sleep quality. The interaction here is additive and generally favorable.

MK-677's Effect on Slow-Wave Sleep

A 1997 randomized placebo-controlled crossover trial in Journal of Clinical Endocrinology and Metabolism (N=8 older adults) found that MK-677 25 mg increased stage IV (slow-wave) sleep by 50% compared with placebo [12]. GH secretion is tightly coupled to slow-wave sleep, and GHSR-1a agonism appears to directly modulate sleep architecture through hypothalamic circuits.

Glycine's Separate Sleep Mechanism

Glycine lowers core body temperature by inducing peripheral vasodilation, a mechanism that differs entirely from GH-mediated slow-wave enhancement [5]. Lowering core body temperature is a well-established physiological signal for sleep onset. The two agents therefore address different aspects of sleep: MK-677 deepens sleep architecture, while glycine may shorten the time needed to fall asleep.

Practical Timing

Taking both within the same 30 to 60 minute window before sleep is pharmacologically reasonable. A single evening dose of glycine (3 to 5 g) combined with MK-677 (10 to 25 mg) covers both sleep-onset and slow-wave objectives without requiring dose separation.

Does Glycine Enhance MK-677's Collagen and Muscle Effects?

This is one of the more rationally motivated reasons people stack these two compounds, and the logic holds up mechanistically.

IGF-1 Provides the Anabolic Signal

MK-677 raises IGF-1, the primary mediator of collagen gene expression (COL1A1, COL3A1) in fibroblasts [13]. A 24-week trial in Journal of Clinical Endocrinology and Metabolism (N=24 older adults) showed that MK-677 25 mg daily raised IGF-1 by 39% above baseline, which was associated with improved nitrogen balance and lean body mass [14].

Glycine Provides the Substrate

Without adequate glycine, upregulated collagen gene expression cannot translate into increased collagen protein output. Research published in Amino Acids estimated that the conditionally essential glycine deficit in typical adults is approximately 10 g per day when full collagen synthesis demand is accounted for [9]. Supplementing 5 to 15 g of glycine daily may close that substrate gap.

Combined Theoretical Benefit

The table below illustrates how MK-677 and glycine address complementary steps in the collagen synthesis cascade:

| Step | Rate-Limited By | Agent That Addresses It | |------|----------------|------------------------| | Collagen gene transcription (COL1A1) | IGF-1 signaling | MK-677 (via raised IGF-1) | | Hydroxylation of proline/lysine | Vitamin C availability | Neither (requires ascorbate separately) | | Glycine incorporation into Gly-X-Y repeats | Free glycine pool | Glycine supplementation | | Cross-linking into mature fibrils | Copper-dependent lysyl oxidase | Neither |

This framework suggests that MK-677 and glycine address two different bottlenecks simultaneously. Whether this translates into measurably superior connective-tissue outcomes in humans has not been tested in a controlled trial.

Glycemic Safety: The Most Important Monitoring Concern

Glucose dysregulation is the most clinically significant risk associated with long-term MK-677 use, and glycine co-administration does not eliminate that risk.

MK-677's Insulin Resistance Mechanism

MK-677 raises GH, which increases hepatic glucose production and reduces peripheral insulin sensitivity through post-receptor inhibition of the insulin signaling cascade [11]. The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency notes that GH excess consistently reduces insulin sensitivity in a dose-dependent manner [15].

Glycine's Partial Counter-Effect

The GLP-1-stimulating effect of glycine is real but modest. The 12% reduction in postprandial glucose AUC observed in the 2018 Clinical Nutrition trial [8] is unlikely to fully counteract MK-677's insulin resistance in individuals predisposed to glucose intolerance. Do not assume glycine makes MK-677 glycemically safe.

Recommended Monitoring Protocol

Anyone combining these two agents should follow this minimum glucose surveillance schedule:

• Fasting glucose at baseline, 6 weeks, and 12 weeks
• HbA1c at baseline and every 3 months thereafter
• Discontinue MK-677 if fasting glucose exceeds 126 mg/dL on two separate measurements or HbA1c reaches 6.5%

The American Diabetes Association's 2024 Standards of Medical Care define prediabetes as fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4% [16]. Individuals already in that range before starting MK-677 face elevated risk and require more frequent monitoring.

Who Should Be Most Cautious With This Combination?

Pre-Diabetic and Diabetic Individuals

If your fasting glucose is already above 100 mg/dL, the insulin-resistance signal from MK-677 may be enough to push you into overt hyperglycemia. Glycine's modest glycemic benefit does not change that risk calculus meaningfully.

Individuals With Edema or Fluid Retention

Both GH excess and high glycine intake (above 15 g/day) have been associated with mild fluid retention [2, 9]. If lower-limb swelling appears, reduce or discontinue MK-677 first, as it is the stronger driver of that effect.

Older Adults

The MK-677 trials that showed increased slow-wave sleep and lean mass gains recruited adults aged 60 to 81 [12, 14]. That population also showed greater rates of glucose elevation. Glycine's safety profile in older adults is well-established, with doses up to 15 g/day demonstrating no serious adverse events in trials lasting up to 12 weeks [17].

Dose and Timing Summary

No human trial has established an optimal MK-677 plus glycine protocol. The following ranges reflect the doses used in published human studies for each agent individually:

| Parameter | MK-677 | Glycine | |-----------|--------|---------| | Studied dose range | 10 to 50 mg/day | 3 to 15 g/day | | Optimal single dose (per trial data) | 25 mg | 3 to 5 g (sleep); up to 15 g (collagen) | | Timing | 30 to 60 min before sleep | Same window; co-administration is fine | | Half-life | ~24 hours [2] | ~30 to 45 min (rapidly cleared) [4] | | Dose separation needed? | No | No |

What Do Physicians at HealthRX Recommend?

The HealthRX medical team does not prescribe or endorse MK-677 for off-label use, as it carries no FDA approval and no established long-term safety data in general populations. Glycine at doses of 3 to 15 g/day has a well-documented safety record in short-term human trials [5, 6, 17].

If a patient is already taking MK-677 and asks about adding glycine, the conversation should center on glucose monitoring, not interaction risk, because the pharmacokinetic profile is clean. The Endocrine Society's position on unapproved GH secretagogues states: "The use of growth hormone secretagogues in healthy adults is not recommended outside of controlled clinical trials" [15].

Glycine itself carries no comparable regulatory concern. It is Generally Recognized as Safe (GRAS) by the FDA for use as a food additive [18].